CathVision announces first patient enroled in persistent AF study


cathvisionCathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the electrophysiology (EP) lab, today announced initial patient enrolment of a follow-on clinical study to demonstrate the value of the Signal Complexity algorithm led by Tom De Potter (OLV Hospital, Aalst, Belgium).

More than 46 million patients worldwide are estimated to suffer from atrial fibrillation (AF). As prevalence increases due to health factors such as obesity, hypertension, and physical inactivity, it is anticipated that as many as one in three individuals older than 40 will experience AF. Seventy-five percent of all AF patients have persistent or permanent forms of AF; freedom from AF at 12 months following therapy is usually found to be approximately 50 percent demonstrating the opportunity to integrate technology that can improve effectiveness.

“When an ablation procedure starts and ends in AF rhythm, delivering a lasting therapy impact on AF cannot be accurately visualised in-procedure today,” said De Potter. “It is often difficult to understand if the ablation strategy is progressing positively. This has an impact both on the duration and on the outcome of the procedure. There is outstanding value in integrating a reliable solution that affirms the ablation impact.”

The Signal Complexity algorithm is designed to measure and visualise rhythm parameters such as cycle length, variability, fractionation, and dominant frequency in real time and track the progress of ablation during persistent atrial fibrillation (AF) procedures. The algorithm provides automated analyses of high-fidelity, low-noise cardiac data from the ECGenius system, CathVision’s EP recording technology, that can help physicians improve clinical outcomes and efficiency. De Potter will specifically assess the clinical utility of Signal Complexity to analyse the impact of ablation therapy in coordination with pulmonary vein isolation (PVI) plus individually mapped ablation targets.

Signal Complexity is part of CathVision’s Cardialytics suite of artificial intelligence-powered analytics, currently in development. The Cardialytics suite includes Signal Complexity, PVI analyser, and FaST mapping. In November of 2022, CathVision announced the clinical evaluation of the Signal Complexity algorithm at NYU Langone Health; 28 patients have been enrolled to date. Data will be presented at the upcoming 2023 Heart Rhythm Society (April 19–21, New Orleans, USA) meeting.

“We remain committed to providing clinicians with substantiated value,” said Mads Matthiesen, CEO of CathVision. “It’s exhilarating to observe the accumulation of clinical evidence supporting the need for the ECGenius system and Cardialytics suite as we look forward to strategic progression that will cement a new era of EP recording systems.”


Please enter your comment!
Please enter your name here